LAVA Therapeutics N.V. (LVTX)
After hours:
| Previous Close | 2.7000 |
| Open | 2.7000 |
| Bid | 2.6200 x 100 |
| Ask | 2.6900 x 100 |
| Day's Range | 2.6000 - 2.8000 |
| 52 Week Range | 1.1310 - 6.4700 |
| Volume | |
| Avg. Volume | 1,095,180 |
| Market Cap | 70.981M |
| Beta (5Y Monthly) | 0.68 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.5700 |
| Earnings Date | Jun 06, 2024 - Jun 10, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireLAVA Provides Business Updates and Reports First Quarter 2024 Financial Results
LAVA-1207 dose escalation progressing in Phase 1/2a trial in prostate cancer, with pembrolizumab combination expected to begin in Q2 2024Received $7.0 million clinical development milestone from Pfizer for PF-08046052 (formerly LAVA-1223) in Phase 1LAVA-1266 on track for Q2 2024 IND submissionStrong balance sheet with cash of $94.6 million supports runway into 2026 UTRECHT, The Netherlands and PHILADELPHIA, May 21, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Compa
- GlobeNewswire
LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference
UTRECHT, The Netherlands and PHILADELPHIA, May 06, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” or “Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma-delta (δ2) T cell engagers, today announced that Stephen Hurly, President and Chief Executive Officer of LAVA Therapeutics, will participate in a fireside chat at the Citizens JMP Life Sciences Conference. Presentation Details Format: Fireside
Simply Wall St.LAVA Therapeutics Full Year 2023 Earnings: Revenues Disappoint
LAVA Therapeutics ( NASDAQ:LVTX ) Full Year 2023 Results Key Financial Results Net loss: US$42.0m (loss widened by 32...
